Lead Sponsor

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Subjects who participated in the preceding A0081244 double-blind trial and completed at least through Visit 9 of that trial.
•Subjects with painful distal sensory polyneuropathy (DSP) interested in treatment based on investigator's clinical judgment.
•Subjects who had acceptable tolerability of study drug in A0081244.

•Clinically significant or unstable conditions that, in the opinion of the investigator, would compromise participation in the study. This includes, for example, medical conditions such as, but not limited to: hepatic, renal, respiratory, hematological, immunological, cardiovascular diseases, arrhythmia, inflammatory or rheumatologic disease, active infections, symptomatic peripheral vascular disease, psychiatric illness, and untreated endocrine disorders.
•Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
•Active Acquired Immune Deficiency Syndrome (AIDS)- defining Opportunistic Infection (OI) that requires hospitalization.

Related studies

NCT07231419 · Diabetic Peripheral Neuropathic Pain

NCT06614322 · Painful Peripheral Neuropathy, Diabetic Peripheral Neuropathic Pain (DPN), and more

NCT05986292 · Osteoarthritis, Knee, Diabetic Neuropathic Pain, and more

NCT07057128 · Neuropathic Pain, Central Sensitization, and more

NCT07493226 · Frozen Shoulder, Adhesive Capsulitis, and more

Pregabalin Trial In HIV Neuropathic Pain